or Try an Advanced Search...

    ETF Components for HRTS - Tema Cardiovascular and Metabolic ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    VRTX C -0.05 5.24
    LLY C 0.29 5.03
    NVO C 0.87 4.91
    AMGN B 0.86 4.57
    DXCM D 1.76 4.07
    EW D 2.04 2.98
    CYTK D -1.78 2.93
    MDT D 0.75 2.87
    ASND D 0.44 2.76

    Represented by ETF Holdings

    Keywords: S&P 500 Diabetes Medicine Growth Hormone Hypertension Insulin Nasdaq 100 Neuroscience Obesity Pharmaceutical Products Biopharmaceutical Biotechnology Bone Breakthrough Therapy Catheter Disease Dysfunction Endocrine System Endocrinology Growth Hormone Deficiency
    Industries: Biotechnology Drug Manufacturers - Major Medical Devices Diagnostics & Research

    Recent News for Tema Cardiovascular and Metabolic ETF & its Holdings

    Date Stock Title
    May 9 ASND Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
    May 9 LLY Making Money Off the Weight-Loss Revolution Has Even Wall Street Befuddled
    May 9 LLY Q1 2024 Amphastar Pharmaceuticals Inc Earnings Call
    May 9 EW The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
    May 9 EW Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
    May 9 VRTX Dow Jones Futures: S&P 500 Holds, Toast Leads 5 New Buys; Robinhood, Arm Are Earnings Movers Late
    May 8 EW Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
    May 8 CYTK Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
    May 8 EW Top Analyst Reports for Salesforce, BP & Southern Co.
    May 8 CYTK Cytokinetics GAAP EPS of -$1.33 misses by $0.18, revenue of $0.84M misses by $0.07M
    May 8 CYTK Cytokinetics Reports First Quarter 2024 Financial Results
    May 8 VRTX A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
    May 8 VRTX Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets
    May 8 MDT 10 Future Dividend Kings in the Next 5 Years or Less
    May 8 LLY Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
    May 8 VRTX Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
    May 8 NVO Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
    May 8 VRTX Vertex Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
    May 8 DXCM Estimating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
    May 8 CYTK Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund advisor generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
    Investment Management Cardiovascular Disease Metabolic Disease Treatment Of Cardiovascular Diseases
    Back to the Main HRTS Page...